Immunomic Therapeutics, a company developing next generation vaccines based on the LAMP-vax platform, and Astellas Pharma have entered into an...
Novavax announced the presentation of new data from the company’s Prepare trial, a global Phase III clinical trial of ResVax...
Purpose: We sought to determine the impact of surgical margin status on overall survival (OS) and recurrence pattern stratified by tumor burden.
High-intensity focused ultrasound (HIFU) and plasma radiofrequency ablation (PRA) have been used to treat recurrent allergic rhinitis (AR); however, there is a lack of literature comparing the efficacy of these 2 methods. We assessed and compared the therapeutic effects of HIFU and PRA on recurrent AR.
Vaxneuvance is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older. See sections 4.4 and 5.1 for information on protection against specific pneumococcal serotypes. The use of Vaxneuvance should be in accordance with official recommendations.